Literature DB >> 8978310

Monitoring of tumor cell purging after highly efficient immunomagnetic selection of CD34 cells from leukapheresis products in breast cancer patients: comparison of immunocytochemical tumor cell staining and reverse transcriptase-polymerase chain reaction.

M Y Mapara1, I J Körner, M Hildebrandt, R Bargou, D Krahl, P Reichardt, B Dörken.   

Abstract

We studied the efficiency of indirect tumor cell purging via enrichment of CD34+ hematopoietic progenitor cells from leukapheresis products (LP) in breast cancer patients based on immunomagnetic selection of CD34+ cells. Detection of tumor cells was made by immunocytochemical staining. In addition, we evaluated the capacity of cytokeratin 19 (CK19)- and a novel epidermal growth factor receptor (EGF-R)-specific reverse transcriptase-polymerase chain reaction (RT-PCR) for monitoring tumor cell depletion. LP from 13 breast cancer patients were analyzed. Twenty-three CD34 selection procedures were performed. A median of 1.4 x 10(10) total nucleated cells ([TNC] range, 0.88 to 3.5 x 10(10)) with a median CD34 purity of 2.5% (range, 0.4% to 6.3%) were entered into the selection procedure. Immunomagnetic CD34 enrichment resulted in a median purity of 83.3% (range, 45% to 95.4%) and a median recovery of 73.2% (range, 22% to 95%). Retransfusion of CD34-selected cells after high-dose chemotherapy resulted in a rapid and sustained hematologic recovery, reaching an absolute neutrophil count of 500/microL at day +10 and platelet count of 20,000/microL at day +11. Tumor cell depletion was quantified by immunocytochemical detection of CK19-positive cells. By this method, a median tumor cell depletion of 1.9 log (range, 0.7 to > 3 log) could be demonstrated. Immunocytochemical detection of tumor cells was more sensitive than RT-PCR, yielding positive results in 81% of LP (17 to 21) versus 58% positive LP (10 of 17). However, EGF-R-based RT-PCR was much more sensitive than CK19-based RT-PCR (10 of 17 v 1 of 17). Despite highly efficient CD34 selection, tumor cells were still detectable after CD34 enrichment using immunocytochemistry and EGF-R-specific RT-PCR. Thus, this novel EGF-R-specific RT-PCR appears to be of value as an additional method to detect contaminating breast cancer cells within LP.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8978310

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  12 in total

1.  The removal of human breast cancer cells from hematopoietic CD34+ stem cells by dielectrophoretic field-flow-fractionation.

Authors:  Y Huang; J Yang; X B Wang; F F Becker; P R Gascoyne
Journal:  J Hematother Stem Cell Res       Date:  1999-10

2.  Differential interaction of magnetic nanoparticles with tumor cells and peripheral blood cells.

Authors:  J H Clement; M Schwalbe; N Buske; K Wagner; M Schnabelrauch; P Görnert; K O Kliche; K Pachmann; W Weitschies; K Höffken
Journal:  J Cancer Res Clin Oncol       Date:  2006-01-24       Impact factor: 4.553

Review 3.  Treatment of breast cancer with chemotherapy in combination with filgrastim: approaches to improving therapeutic outcome.

Authors:  Giuseppe Frasci
Journal:  Drugs       Date:  2002       Impact factor: 9.546

4.  Antibody conjugated magnetic iron oxide nanoparticles for cancer cell separation in fresh whole blood.

Authors:  Hengyi Xu; Zoraida P Aguilar; Lily Yang; Min Kuang; Hongwei Duan; Yonghua Xiong; Hua Wei; Andrew Wang
Journal:  Biomaterials       Date:  2011-09-14       Impact factor: 12.479

5.  Multiplex RT-PCR-based detections of CEA, CK20 and EGFR in colorectal cancer patients.

Authors:  Aikaterini Tsouma; Chrysanthi Aggeli; Panagiotis Lembessis; George-N Zografos; Dimitris-P Korkolis; Dimitrios Pectasides; Maria Skondra; Nikolaos Pissimissis; Anastasia Tzonou; Michael Koutsilieris
Journal:  World J Gastroenterol       Date:  2010-12-21       Impact factor: 5.742

6.  Detection of circulating tumour cells in patients with breast or ovarian cancer by molecular cytogenetics.

Authors:  H Engel; C Kleespies; J Friedrich; M Breidenbach; A Kallenborn; T Schöndorf; H Kolhagen; P Mallmann
Journal:  Br J Cancer       Date:  1999-12       Impact factor: 7.640

7.  Marker genes for circulating tumour cells predict survival in metastasized breast cancer patients.

Authors:  B Weigelt; A J Bosma; A A M Hart; S Rodenhuis; L J van 't Veer
Journal:  Br J Cancer       Date:  2003-04-07       Impact factor: 7.640

8.  Sequential detection of alphafetoprotein-bearing cells in blood stem cell fraction of germ cell tumour patients.

Authors:  T Kasahara; N Hara; V Bilim; Y Tomita; K Saito; K Obara; K Takahashi
Journal:  Br J Cancer       Date:  2001-10-19       Impact factor: 7.640

9.  High-dose chemotherapy followed by reinfusion of selected CD34+ peripheral blood cells in patients with poor-prognosis breast cancer: a randomized multicentre study.

Authors:  C Chabannon; K Cornetta; J P Lotz; C Rosenfeld; M Shlomchik; S Yanovitch; J P Marolleau; G Sledge; G Novakovitch; E F Srour; B Burtness; J Camerlo; G Gravis; J Lee-Fischer; C Faucher; I Chabbert; D Krause; D Maraninchi; B Mills; L Kunkel; F Oldham; D Blaise; P Viens
Journal:  Br J Cancer       Date:  1998-10       Impact factor: 7.640

10.  Significance of hematopoietic surface antigen CD34 in neuroblastoma prognosis and the genetic landscape of CD34-expressing neuroblastoma CSCs.

Authors:  Natarajan Aravindan; Dinesh Babu Somasundaram; Terence S Herman; Sheeja Aravindan
Journal:  Cell Biol Toxicol       Date:  2020-09-26       Impact factor: 6.819

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.